Market Overview

Sage Therapeutics Shares Toppled By Failed Mountain Study Of Depression Drug

Sage Therapeutics Shares Toppled By Failed Mountain Study Of Depression Drug

Shares of thinly-traded SAGE Therapeutics Inc NASDAQ: SAGE) are melting down after the company flunked in a late-stage trial of its lead CNS disorder drug candidate SAGE-217 in major depressive disorder, or MDD.

What Happened To SAGE-217?

Sage said its pivotal Phase 3 MOUNTAIN study evaluating the effect of SAGE-217 on depressive symptoms in adults with MDD did not meet the primary endpoint of a statistically significant reduction from the baseline compared to placebo in the 17-item Hamilton Rating Scale of Depression, HAM-D, total score at Day 15.

SAGE-217, 30 mg, when given once-daily, as an oral treatment produced a mean reduction of 12.6 in HAM-D score compared to 11.2 for placebo. However, at Days 3, 8 and 12, SAGE-217 showed statistically significant reductions in HAM-D score.

Incidentally, Sage said in mid-January its SAGE-217 aced a late-stage trial that evaluated it for post-partum depression, or PPD, meeting both primary and secondary endpoints.

See Also: This Biotech Is On Track To End 2019 As The Best Performing Stock In The Sector

What's Next For Sage

The company said post-hoc analysis of the MOUNTAIN study showed about 9% of patients in the 30mg group have no measurable drug concentration, which tantamounts to non-compliance with respect to the dosing.

"This study did not meet the primary endpoint. With that, the data are supportive of the activity of SAGE-217 in MDD given the statistical significance at the majority of timepoints, and in relevant populations," said CEO Jeff Jonas.

"As a designated breakthrough therapy, we are evaluating the path forward to more fully inform a potentially expedited pathway to approval, and any amendments we might consider to the ongoing SAGE-217 pivotal program," said Steve Kanes, Chief Medical Officer at Sage.

The company is also evaluating SAGE-217 in separate late-stage studies in insomnia and treatment-resistant depression.

Sage's stock tumbled 55% to $68 per share at time of publication.

Posted-In: major depressive disorder SAGE-217Biotech News Top Stories Movers Trading Ideas General Best of Benzinga


Related Articles (SAGE)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at